Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Molecular Diagnosis for Personalized Target Therapy in Gastric Cancer

  • Cho, Jae Yong (Department of Medical Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine)
  • Received : 2013.05.15
  • Accepted : 2013.06.18
  • Published : 2013.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Gastric cancer is the second leading cause of cancer-related deaths worldwide. In advanced and metastatic gastric cancer, the conventional chemotherapy with limited efficacy shows an overall survival period of about 10 months. Patient specific and effective treatments known as personalized cancer therapy is of significant importance. Advances in high-throughput technologies such as microarray and next generation sequencing for genes, protein expression profiles and oncogenic signaling pathways have reinforced the discovery of treatment targets and personalized treatments. However, there are numerous challenges from cancer target discoveries to practical clinical benefits. Although there is a flood of biomarkers and target agents, only a minority of patients are tested and treated accordingly. Numerous molecular target agents have been under investigation for gastric cancer. Currently, targets for gastric cancer include the epidermal growth factor receptor family, mesenchymal-epithelial transition factor axis, and the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathways. Deeper insights of molecular characteristics for gastric cancer has enabled the molecular classification of gastric cancer, the diagnosis of gastric cancer, the prediction of prognosis, the recognition of gastric cancer driver genes, and the discovery of potential therapeutic targets. Not only have we deeper insights for the molecular diversity of gastric cancer, but we have also prospected both affirmative potentials and hurdles to molecular diagnostics. New paradigm of transdisciplinary team science, which is composed of innovative explorations and clinical investigations of oncologists, geneticists, pathologists, biologists, and bio-informaticians, is mandatory to recognize personalized target therapy.

Keywords

References

  1. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-856. https://doi.org/10.1038/nrc1739
  2. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001;291:1304-1351. https://doi.org/10.1126/science.1058040
  3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. https://doi.org/10.3322/caac.20107
  4. Shah MA, Ajani JA. Gastric cancer--an enigmatic and heterogeneous disease. JAMA 2010;303:1753-1754. https://doi.org/10.1001/jama.2010.553
  5. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402. https://doi.org/10.1038/35006081
  6. Park DW, Lee KJ, Jin SH, Lee JH, Min JS, Park SH, et al. Phenotypic differences of gastric cancer according to the Helicobacter pylori infection in Korean patients. J Gastric Cancer 2010;10:168-174. https://doi.org/10.5230/jgc.2010.10.4.168
  7. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998;392:402-405. https://doi.org/10.1038/32918
  8. Study Group of Millennium Genome Project for Cancer, Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 2008;40:730-740. https://doi.org/10.1038/ng.152
  9. Tay ST, Leong SH, Yu K, Aggarwal A, Tan SY, Lee CH, et al. A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res 2003;63:3309-3316.
  10. Kim B, Bang S, Lee S, Kim S, Jung Y, Lee C, et al. Expression profiling and subtype-specific expression of stomach cancer. Cancer Res 2003;63:8248-8255.
  11. Chen X, Leung SY, Yuen ST, Chu KM, Ji J, Li R, et al. Variation in gene expression patterns in human gastric cancers. Mol Biol Cell 2003;14:3208-3215. https://doi.org/10.1091/mbc.E02-12-0833
  12. Lee HS, Cho SB, Lee HE, Kim MA, Kim JH, Park do J, et al. Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin Cancer Res 2007;13:4154-4163. https://doi.org/10.1158/1078-0432.CCR-07-0173
  13. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011;141:476-485. https://doi.org/10.1053/j.gastro.2011.04.042
  14. Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet 2009;5:e1000676. https://doi.org/10.1371/journal.pgen.1000676
  15. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697. https://doi.org/10.1016/S0140-6736(10)61121-X
  16. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-3976. https://doi.org/10.1200/JCO.2011.36.2236
  17. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008;15:69-79. https://doi.org/10.1245/s10434-007-9596-0
  18. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-278. https://doi.org/10.1093/annonc/mdi064
  19. Yang J, Luo H, Li Y, Li J, Cai Z, Su X, et al. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys 2012;62:221-228. https://doi.org/10.1007/s12013-011-9286-1
  20. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-1902. https://doi.org/10.1002/(SICI)1097-0142(19990501)85:9<1894::AID-CNCR3>3.0.CO;2-J
  21. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 2011;25:1517-1524.
  22. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012;61:673-684. https://doi.org/10.1136/gutjnl-2011-301839
  23. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 2009;15:1821-1829. https://doi.org/10.1158/1078-0432.CCR-08-2138
  24. Claerhout S, Lim JY, Choi W, Park YY, Kim K, Kim SB, et al. Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One 2011;6:e24662. https://doi.org/10.1371/journal.pone.0024662
  25. Virág L, Szabo C. The therapeutic potential of poly (ADPribose) polymerase inhibitors. Pharmacol Rev 2002;54:375-429. https://doi.org/10.1124/pr.54.3.375
  26. Bang YJ. A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study. J Clin Oncol 2012;30(suppl 34):abstr 11.
  27. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al; Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14:490-499. https://doi.org/10.1016/S1470-2045(13)70102-5
  28. Waddell TS, Chau I, Barbachano Y, Gonzalez de Castro D, Wotherspoon A, Saffery C. A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). J Clin Oncol 2012;30(suppl; abstr LBA4000).
  29. Fuchs CS, Tomasek J, Cho JY, Dumitru F, Passalacqua R, Goswami C, et al. REGARD: a phase III, randomized, doubleblinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine- containing combination therapy. J Clin Oncol 2012;30(suppl 34; abstr LBA5).
  30. Van Cutsem E, Yeh KH, Bang YJ, Shen L, Ajani JA, Bai YX, et al. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. J Clin Oncol 2012;30(suppl 4; abstr LBA3).
  31. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012;30:2119-2127. https://doi.org/10.1200/JCO.2011.39.9824
  32. Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011;17:2693-2701. https://doi.org/10.1158/1078-0432.CCR-10-2203
  33. Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, Kim SM, et al. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res 2011;17:1850-1857. https://doi.org/10.1158/1078-0432.CCR-10-2180
  34. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med 2004;351:2817-2826. https://doi.org/10.1056/NEJMoa041588
  35. Kim YH, Liang H, Liu X, Lee JS, Cho JY, Cheong JH, et al. $AMPK{\alpha}$ modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res 2012;72:2512-2521. https://doi.org/10.1158/0008-5472.CAN-11-3870
  36. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012;44:570-574. https://doi.org/10.1038/ng.2246
  37. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010;11:136-146. https://doi.org/10.1016/S1470-2045(09)70343-2

Cited by

  1. miR‐129‐1‐3p Promote BGC‐823 Cell Proliferation by Targeting PDCD2 vol.297, pp.12, 2013, https://doi.org/10.1002/ar.23003
  2. The novel long noncoding RNA AC138128.1 may be a predictive biomarker in gastric cancer vol.31, pp.11, 2013, https://doi.org/10.1007/s12032-014-0262-7
  3. Low expression of lncRNA-HMlincRNA717 in human gastric cancer and its clinical significances vol.35, pp.10, 2013, https://doi.org/10.1007/s13277-014-2243-z
  4. Vibrational spectroscopy for cancer diagnostics vol.6, pp.12, 2014, https://doi.org/10.1039/c3ay42235f
  5. Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial vol.10, pp.9, 2013, https://doi.org/10.2217/fon.14.106
  6. Microarray analysis in gastric cancer: A review vol.20, pp.34, 2014, https://doi.org/10.3748/wjg.v20.i34.11972
  7. The use of high-throughput screening in identifying chemotherapeutic agents for gastric cancer vol.6, pp.18, 2013, https://doi.org/10.4155/fmc.14.131
  8. Nursing Implications of Personalized and Precision Medicine vol.30, pp.2, 2014, https://doi.org/10.1016/j.soncn.2014.03.007
  9. Prognostic role of lemur tyrosine kinase 3 in postoperative gastric cancer vol.2, pp.5, 2013, https://doi.org/10.3892/mco.2014.301
  10. Gastric juice long noncoding RNA used as a tumor marker for screening gastric cancer vol.120, pp.21, 2014, https://doi.org/10.1002/cncr.28882
  11. Identification of Differentially-expressed Genes in Intestinal Gastric Cancer by Microarray Analysis vol.12, pp.6, 2013, https://doi.org/10.1016/j.gpb.2014.09.004
  12. Oncogenic HER2 fusions in gastric cancer vol.13, pp.None, 2013, https://doi.org/10.1186/s12967-015-0476-2
  13. Bio-functionalized dense-silica nanoparticles for MR/NIRF imaging of CD146 in gastric cancer vol.10, pp.None, 2013, https://doi.org/10.2147/ijn.s62837
  14. Synthesis, Molecular Modeling, and Biological Evaluation of Novel Chiral Thiosemicarbazone Derivatives as Potent Anticancer Agents vol.27, pp.2, 2013, https://doi.org/10.1002/chir.22408
  15. Lactotransferrin expression is downregulated and affects the mitogen-activated protein kinase pathway in gastric cancer vol.9, pp.5, 2015, https://doi.org/10.3892/ol.2015.3011
  16. Implication of Leptin-Signaling Proteins and Epstein-Barr Virus in Gastric Carcinomas vol.10, pp.7, 2015, https://doi.org/10.1371/journal.pone.0130839
  17. Recent advances in the molecular diagnostics of gastric cancer vol.21, pp.34, 2013, https://doi.org/10.3748/wjg.v21.i34.9838
  18. ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer vol.43, pp.12, 2016, https://doi.org/10.1007/s00259-016-3442-1
  19. Metastatic gastric cancer treatment: Second line and beyond vol.22, pp.11, 2013, https://doi.org/10.3748/wjg.v22.i11.3069
  20. Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature vol.22, pp.26, 2013, https://doi.org/10.3748/wjg.v22.i26.5896
  21. Expression of FoxM1 and the EMT-associated protein E-cadherin in gastric cancer and its clinical significance vol.12, pp.4, 2016, https://doi.org/10.3892/ol.2016.4917
  22. Differential expression profiles of long non-coding RNAs reveal potential biomarkers for identification of human gastric cancer vol.35, pp.3, 2013, https://doi.org/10.3892/or.2015.4531
  23. Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis vol.7, pp.11, 2013, https://doi.org/10.7150/jca.15578
  24. Decreased RNA-binding motif 5 expression is associated with tumor progression in gastric cancer vol.39, pp.3, 2017, https://doi.org/10.1177/1010428317694547
  25. NDRG4 hypermethylation is a potential biomarker for diagnosis and prognosis of gastric cancer in Chinese population vol.8, pp.5, 2013, https://doi.org/10.18632/oncotarget.14099
  26. Overexpression of Neuron-Specific Enolase as a Prognostic Factor in Patients with Gastric Cancer vol.17, pp.3, 2013, https://doi.org/10.5230/jgc.2017.17.e28
  27. Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma vol.17, pp.None, 2013, https://doi.org/10.1186/s12885-017-3051-9
  28. Gastric Cancer Cell Lines Have Different MYC -Regulated Expression Patterns but Share a Common Core of Altered Genes vol.2018, pp.None, 2013, https://doi.org/10.1155/2018/5804376
  29. Preoperative Tumor Markers Independently Predict Survival in Stage III Gastric Cancer Patients: Should We Include Tumor Markers in AJCC Staging? vol.25, pp.9, 2013, https://doi.org/10.1245/s10434-018-6634-z
  30. CTNNBIP1 downregulation is associated with tumor grade and viral infections in gastric adenocarcinoma vol.234, pp.3, 2013, https://doi.org/10.1002/jcp.27106
  31. Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma vol.3, pp.1, 2013, https://doi.org/10.1038/s42003-020-1077-z
  32. LncRNA FLVCR1-AS1 promotes proliferation, migration and activates Wnt/β-catenin pathway through miR-381-3p/CTNNB1 axis in breast cancer vol.20, pp.None, 2020, https://doi.org/10.1186/s12935-020-01247-2
  33. Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer vol.20, pp.4, 2013, https://doi.org/10.5230/jgc.2020.20.e33
  34. Three-Dimensional Printing for Cancer Applications: Research Landscape and Technologies vol.14, pp.8, 2021, https://doi.org/10.3390/ph14080787